Publication

HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.

McCormack, Mark
; 
Alfirevic, Ana
; 
Bourgeois, Stephane
; 
Farrell, John J
; 
Kasperavičiūtė, Dalia
; 
Carrington, Mary
; 
Sills, Graeme J
; 
Marson, Tony
; 
Jia, Xiaoming
; 
de Bakker, Paul I W
... show 10 more
Authors
McCormack, Mark
 Alfirevic, Ana
 Bourgeois, Stephane
 Farrell, John J
 Kasperavičiūtė, Dalia
 Carrington, Mary
 Sills, Graeme J
 Marson, Tony
 Jia, Xiaoming
 de Bakker, Paul I W
 Chinthapalli, Krishna
 Molokhia, Mariam
 Johnson, Michael R
 O'Connor, Gerard D
 Chaila, Elijah
 Alhusaini, Saud
 Shianna, Kevin V
 Radtke, Rodney A
 Heinzen, Erin L
 Walley, Nicole
 Pandolfo, Massimo
 Pichler, Werner
 Park, B Kevin
 Depondt, Chantal
 Sisodiya, Sanjay M
 Goldstein, David B
 Deloukas, Panos
 Delanty, Norman
 Cavalleri, Gianpiero L
 Pirmohamed, Munir
Advisors
Editors
Other Contributors
Departments
Molecular and Cellular Therapeutics, the Royal College of Surgeons in Ireland, Dublin, Ireland.
Date
2011-03-24
Date Submitted
Keywords
Other Subjects
Subject Mesh
Anticonvulsants
Carbamazepine
Drug Hypersensitivity
European Continental Ancestry Group
Exanthema
Genome-Wide Association Study
Genotype
HLA-A Antigens
Histocompatibility Testing
Humans
Polymorphism, Single Nucleotide
Stevens-Johnson Syndrome
Planned Date
Start Date
Collaborators
Principal Investigators
Alternative Titles
Publisher
URI
http://hdl.handle.net/10147/229952
Abstract
Carbamazepine causes various forms of hypersensitivity reactions, ranging from maculopapular exanthema to severe blistering reactions. The HLA-B*1502 allele has been shown to be strongly correlated with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) in the Han Chinese and other Asian populations but not in European populations.
Language
en
Citation
HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. 2011, 364 (12):1134-43 N. Engl. J. Med.
ISSN
1533-4406
eISSN
ISBN
DOI
10.1056/NEJMoa1013297
PMID
21428769
PMCID
Sponsorships
Funding Sources
Funding Amounts
Grant Identifiers
Methodology
Duration
Ethical Approval